References
- Cole JC, Sumnall HR. Altered states: the clinical effects of Ecstasy. Pharmacol Ther. 2003;98(1):35–58.
- Burgess C, O’Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry. 2000;15(5):287–294.
- Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with “ecstasy” and “eve” misuse. J Clin Pathol. 1996;49(2):149–153.
- Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001;165(7):917–928.
- Mende I, Böhm R, Regenthal R, et al. Cardiac arrest caused by an ecstasy intoxication. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005;40(12):762–765.
- Scheinman MM. History of Wolff-Parkinson-White syndrome. PACE. 2005;28(2):152–156.
- Obeyesekere M, Gula LJ, Skanes AC, et al. Risk of sudden death in Wolff-Parkinson-White syndrome: how high is the risk? Circulation. 2012;125(5):659–660.
- Dreifus LS, Haiat R, Watanabe Y, et al. Ventricular fibrillation. A possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome. Circulation. 1971;43(4):520–527. .
- Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome: results of a prospective long-term electrophysiological follow-up study. Circulation. 2012;125(5):661–668. .
- Olen MM, Baysa SJ, Rossi A, et al. Wolff-Parkinson-White Syndrome: a stepwise deterioration to sudden death. Circulation. 2016;133(1):105–106. .
- Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995;76(7):492–494. .
- Brugada J, Keegan R. Asymptomatic ventricular pre-excitation: between sudden cardiac death and catheter ablation. Arrhythmia Electrophysiol. 2018;7(1):32–38.
- Ghuran A. The cardiac complications of recreational drug use. West J Med. 2000;173(6):412–415.
- Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83(6):627–633.
- Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96(6):678–685.
- Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent—the agony of ecstasy. Pediatr Emerg Care. 2003;19(5):348–349.
- Suarez RV, Riemersma R. “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol. 1988;9(4):339–341.
- Erowid. MDA Dosage [web page]. 2000 [cited 2017 Sept 06]. Available from:https://erowid.org/chemicals/mda/mda_dose.shtml.
- European Resuscitation Council. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care - An international consensus on science. Part 8: advanced challenges in resuscitation. Section 2: toxicology in emergency cardiovascular care. Resuscitation. 2000;46(1–3):261–266. .
- Bougouin W, Cariou A. Should we ‘block’ refractory ventricular fibrillation? Resuscitation. 2016;107:A9–A10.
- Lee YH, Lee KJ, Min YH, et al. Refractory ventricular fibrillation treated with esmolol. Resuscitation. 2016;107:150–155.